We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+28.17%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.72B
AUM Growth
+$1.22B
Cap. Flow
+$567M
Cap. Flow %
9.91%
Top 10 Hldgs %
84.78%
Holding
119
New
24
Increased
23
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.2M
2
MDCO
Medicines Co
MDCO
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.9M
4
INCY icon
Incyte
INCY
+$9.54M
5
NKTR icon
Nektar Therapeutics
NKTR
+$7.71M

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$27M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M
4
ZTO icon
ZTO Express
ZTO
+$6.21M
5
SAGE
Sage Therapeutics
SAGE
+$6.14M

Sector Composition

Rank Sector Weight
1 Consumer Staples 34.97%
2 Healthcare 25.04%
3 Consumer Discretionary 17.19%
4 Financials 0.66%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
51
Seres Therapeutics
MCRB
$45.3M
$6.78M 0.12%
30,000
– –
ARAV
52
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.11M 0.11%
58,333
+8,333
+17% +$895K
ANAB icon
53
AnaptysBio
ANAB
$1.55B
$5.98M 0.1%
250,000
+205,310
+459% +$5.16M
JUNO
54
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.98M 0.1%
200,000
– –
HZNP
55
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.93M 0.1%
+500,000
New +$6.22M
MET icon
56
MetLife
MET
$62.4B
$5.49M 0.1%
112,200
-112,200
-50% -$5.2M
AXDX
57
DELISTED
Accelerate Diagnostics
AXDX
$5.47M 0.1%
+20,000
New +$5.42M
BLUE
58
CALL
DELISTED
bluebird bio
BLUE
$5.25M 0.09%
+3,860
New +$4.66M
MGNX icon
59
MacroGenics
MGNX
$233M
$5.25M 0.09%
300,000
– –
SGEN
60
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$5.17M 0.09%
+100,000
New +$6.36M
AGIO icon
61
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$5.14M 0.09%
100,000
– –
SRPT icon
62
Sarepta Therapeutics
SRPT
$1.64B
$5.06M 0.09%
150,000
-50,000
-25% -$1.63M
FOLD
63
CALL
DELISTED
Amicus Therapeutics
FOLD
$5.04M 0.09%
+500,000
New +$4.02M
TGTX icon
64
TG Therapeutics
TGTX
$8.19B
$5.03M 0.09%
+500,000
New +$5.6M
BCRX icon
65
BioCryst Pharmaceuticals
BCRX
$2.42B
$4.73M 0.08%
850,000
+350,000
+70% +$2.13M
CCXI
66
DELISTED
ChemoCentryx, Inc.
CCXI
$4.68M 0.08%
500,000
-46,278
-8% -$340K
FPRX
67
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.52M 0.08%
+150,000
New +$4.68M
ACIU icon
68
AC Immune
ACIU
$231M
$4.4M 0.08%
500,000
– –
AKAO
69
DELISTED
Achaogen Inc
AKAO
$4.35M 0.08%
200,000
+140,000
+233% +$3.2M
SNDX icon
70
Syndax Pharmaceuticals
SNDX
$1.7B
$4.19M 0.07%
300,000
+100,000
+50% +$1.14M
ARRY
71
CALL
DELISTED
Array Biopharma Inc
ARRY
$4.18M 0.07%
+500,000
New +$4.09M
SIOX
72
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.06M 0.07%
21,875
-9,375
-30% -$1.64M
LCTX icon
73
Lineage Cell Therapeutics
LCTX
$264M
$4.04M 0.07%
1,465,383
– –
NTLA icon
74
Intellia Therapeutics
NTLA
$1.51B
$4M 0.07%
250,000
– –
SGEN
75
DELISTED
Seagen Inc. Common Stock
SGEN
$3.88M 0.07%
75,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2017 Portfolio in Review

As of Q2 2017, Artal Group held 119 positions worth $5.72B, up 27% from $4.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group deployed $567M of net new capital in Q2 2017, opening 24 new positions and adding to 23 existing holdings. Its largest new stake was Goldman Sachs: 100,000 shares worth $22.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 35% of assets, down from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Athene Holding Ltd. Class A Common Shares, an estimated $12.8M trimmed.

  • Artal Group's largest Q2 2017 buy was Goldman Sachs: 100,000 shares worth $22.2M.
  • Artal Group added most to Medicines Co in Q2 2017, an estimated $11.1M increase.
  • Artal Group's biggest Q2 2017 reduction was Athene Holding Ltd. Class A Common Shares, cutting an estimated $12.8M.
  • Artal Group fully exited Alibaba in Q2 2017, selling an estimated $27M.
  • Artal Group's ten largest holdings make up 85% of its $5.72B portfolio in Q2 2017.
  • Artal Group opened 24 new positions and closed 11 in Q2 2017.
  • Artal Group's portfolio value rose 27% quarter-over-quarter to $5.72B.

Based on Artal Group's 13F filing for Q2 2017, filed 11 Aug 2017.